Publication date: May 2012 |Format: PDF |Pages: 161
An incisive, dynamic analytical report that uses insight from the most influential key opinion leaders (KOLs) in Alzheimer’s disease (AD) to map the current treatment landscape and identify future trends.
Alzheimer’s Disease: Beta-amyloid light fades to leave development hole
By the end of 2012, the Alzheimer’s disease market will reach a pivotal stage with the release of Phase III results of disease-modifying therapies, and new research into biomarkers to aid early AD diagnosis. If positive, these results will validate the beta amyloid approach, but if negative, it will represent a huge blow to Alzheimer’s research. Recent trends in the AD market also represent a clear shift in researchers’ approaches to detecting, treating and preventing AD.
‘Therapy Trends: Alzheimer’s Disease’ is compiled from exclusive, in-depth interviews with the world’s leading KOLs in AD. It identifies and analyses the major factors, advances and trends currently influencing the AD treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future AD management.
Drive your strategic decision-making with inside intelligence ‘Therapy Trends: Alzheimer’s Disease’ disseminates the critical opinions of KOLs, giving you greater insight to the latest AD market advances. This information includes:
•The most relevant factors driving the global AD market, allowing you to start planning your business strategies without delay
•First-hand feedback from the most influential AD KOLs, giving you the strategic head-start you need for informed market decision-making
•KOL consensus on the future AD treatment algorithm helping you identify the clinical evidence and potential use of new AD therapies
•KOL opinions on unmet needs and industry challenges allowing you to recognised and capitalise on possible commercial AD opportunities
•On-going AD report updates for 12 months providing you with fast KOL feedback on the significance of industry events within days of their occurrence.
Critical questions answered
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how AD clinical research will shape the future market.
These KOLs provided answers to some critical questions regarding the global AD market: